N-Acetyl Selank Amidate

N-Acetyl Selank Amidate Cognitive & Nootropic Overview

N-Acetyl Selank Amidate is a meticulously engineered neurotrophic compound, designed to heavily bias central nervous activity toward synaptic growth, neuronal protection, and optimized cerebral signaling efficiency.

Physiochemical Profile

Parameter	Value
Molecular Formula	C35H60N12O9
Molecular Mass	808.9 g/mol
Assay Purity	>99.0%
Appearance	White lyophilized cake

Figure 1: N-Acetyl Selank Amidate Blood-Brain Barrier (BBB) Permeation

Cerebral Mechanism of Action

Detailed cascade of actions triggering its primary nootropic effects:

1. The bio-active Tuftsin analogue equipped with enzymatic armor (N-Acetyl and Amidation).
2. Exhibits a radically extended half-life allowing prolonged exposure in the CNS.
3. Suppresses panic-induced enkephalinase activity over a much steadier curve.
4. Forces deeper suppression of excessive localized cortisol output in the hippocampus.
5. Maintains absolute cognitive clarity without causing motor-skill sedation.

Figure 2: Rate of Synaptogenesis / BDNF Expression

Primary Research Outcomes

• Finding 1: The premier anxiolytic peptide formulation for sustaining baseline calm over 24-hour periods.
• Finding 2: Rapidly aborts acute stress responses better than standard Selank.
• Finding 3: Displays immense capability at balancing dopamine cascades preventing 'burnout'.

Stabilized Anxiolytic Immunopeptide

N-Acetyl Selank Amidate applies the same N-terminal acetylation and C-terminal amidation modifications to the Selank heptapeptide. Like its Semax counterpart (NASA), the modifications dramatically improve proteolytic stability and extend the biological half-life, resulting in greater potency per milligram and longer duration of anxiolytic and immunomodulatory effects. The modified Selank retains the full spectrum of GABAergic, serotonergic, and immune-modulating activity of the parent peptide with improved pharmacokinetics.

1. Terminal protection prevents rapid degradation by circulating aminopeptidases and carboxypeptidases that normally clear Selank within minutes.
2. Extended peptide half-life allows more sustained GABA-A receptor allosteric modulation, producing smoother and longer-lasting anxiolysis.
3. The tuftsin core sequence responsible for immune activation is preserved intact within the modified structure.
4. Increased lipophilicity from the acetyl group may improve transmucosal absorption across the nasal epithelium by 20–40%.
5. Higher sustained brain concentrations allow the full genomic anxiolytic program (36 GABAergic genes) to be engaged more completely with each dose.

Comparative Research Advantages

• Duration: The anxiolytic effect of modified Selank persists for 6–8 hours versus 3–4 hours for standard Selank, reducing the need for multiple daily doses.
• Dose Reduction: Improved bioavailability allows effective anxiolysis at lower microgram doses, improving cost-efficiency for longer research protocols.
• No Sedation: Like standard Selank, the modified version produces anxiolysis without sedation, cognitive impairment, or motor coordination deficits.
• No Dependence: Neither standard nor modified Selank produces physical dependence, tolerance, or withdrawal symptoms, distinguishing them from benzodiazepines.
• Administration: Intranasal delivery, 1–2 times daily. Reconstitute in bacteriostatic water. Store at 2–8°C after reconstitution.